jnj-64413739
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 24, 2017 (NCT03088644)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- P2X purinoceptor 7Radiopharmaceutical
P2RX7 radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1Cc2c(ncn2-c2ncccn2)CN1C(=O)c1ccnc(C(F)(F)F)c1F- Mol. weight
- 406.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068778 ↗
Also known as
- jnj-64413739
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03437590 | Phase 1 | Mar 15, 2018 | Johnson and Johnson |
| NCT03088644 | Phase 1 | Mar 24, 2017 | Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1